The significance of rat liver foci in carcinogenesis testing received major attention following their description in the National Cancer Institute workshop of 1974. However, the biological nature of foci remains uncertain despite numerous studies during the past 15 years. That is, in part, because criteria to define foci have been inconsistent, and studies of spontaneous foci in rats have k n very few. This symposium has demonstrated that the induction or enhancement of rat liver foci, per se, may not provide sufficient evidence to classify a test compound as a carcinogen. Evidence presented suggests that some types of rat liver foci may not be related to carcinogenesis, and there is, consequently, a basis to further subclassify these lesions. In cases where foci are considered to be a part of the neoplastic process, semi-quantitative grading of these lesions, as well as of tumors, according to the extent of their development or progression, may assist in the interpretation of equivocal carcinogenicity test findings.
INTRODUCTION
The National Cancer Institute (NCI) workshop on the classification of hepatocellular lesions in rats held in December 1974 listed "foci of cellular alteration,** among other lesions, as part of a recommended pathological classification (7). The foci were subclassified into: clear cell, eosinophilic or ground glass, basophilic, and mixed types, depending primarily upon tinctorial characteristics of the cytoplasm in H&E-stained sections. A critical morphologic feature of foci was that they did not disrupt the liver architecture; the liver plates of altered cells merged without demarcation with surrounding tissue. The nature of altered foci was acknowledged to be controversial, but it was stated in the published report that ". . . several participants felt that basophilic foci or areas had greater significance with respect to tumor development than did other cellular alterations. Most participants agreed that foci or areas were cytologically similar to the cellular elements of neoplastic nodules and may be part of the spectrum capable of progressing to the formation of nodules."
Despite numerous scientific publications in the 15 years since the NCI workshop describing many and variable enzyme alterations and biological features of foci in animal model systems, the significance of foci in carcinogenicity tests has yet to be adequately resolved. This is, at least in part, because many experiments have not defined the lesions under study by H&E-stained sections, and also because the foci occurring in control animals have not been adequately investigated. It is clear that opinions regarding the significance of foci vary depending upon whether one's experience is largely carcinogenicity testing of unknown chemicals, or research with known hepatocarcinogens and liver tumor model systems. The situation may be analogous to the story of the blind men examining different parts of the same elephant. However, it is also possible that investigators are talking about different lesions. This symposium may begin the process of exploring these 2 possibilities. This paper will address 4 topics related to the evaluation of foci in carcinogenicity tests, and then discuss the significance of these lesions in safety assessment.
SQUIRE
T O X I~U X X C PATHOLOOY 344 rats, where the incidence in 2-year-old females may reach 100% (9) . Rats in general, and Fischer 344 females in particular, appear to be unusual, if not unique, in their propensity to develop spontaneous liver foci. Yet, the average liver tumor rate reported by The National Toxicology Program (NTP) among 1,766 female F344 rats was only 2.7% (3). Sprague-Dawley derived strains have similar liver tumor rates, but spontaneous foci are less frequent than in Fischer rats. And B6C3F1 male mice, which have very high liver tumor rates, have comparatively few spontaneous foci. Despite this lack of correlation, it has been widely accepted that liver foci are part of a spectrum of neoplastic development. This probably stems from the views expressed in 1974 in the NCI workshop. The Environmental Protection Agency (EPA) states that "Foci of cellular alteration are to some extent indicative of an ongoing carcinogenic process and should be used in risk assessments" (2) . It may be necessary to re-examine this position, and also to assess more precisely the significance of different types of foci. The evidence at present strongly suggests we are dealing with more than 1 lesion. This view is supported by Dr. Harada's data, which is presented elsewhere in this journal. He reports that, in the limited NTP material he examined, the socalled "tigroid" basophilic focus, originally described by Bannasch (I), and eosinophilic ground glass foci, both of which are very common in control Fischer 344 rats, were not associated with carcinogenesis. Based upon his review of 4 rat hepatocarcinogens and 3 non-carcinogens, Dr. Harada concluded that the diffuse basophilic foci and those eosinophilic foci he termed "amphophilic" were the types that increased in size and/or number following exposure to a carcinogen. He also reported that clear cell, vacuolated, and mixed foci were increased with carcinogen exposure.
It has also been this author's experience that the basophilic foci associated with carcinogenesis have been more atypical than the so-called tigroid type observed in control animals. In these atypical foci, the individual hepatocytes and their nuclei are enlarged, the cytoplasm is more diffusely basophilic, and the hepatic plate architecture may be disrupted to some degree. I have not observed any association between clear cell or vacuolated foci and carcinogenesis.
Enzymatic alterations have also been reported to differ among different types of foci. However, because of the inconsistent use of standard pathological methods, e.g., H&E stains, general conclusions cannot be drawn and such findings have not materially assisted in the interpretation of carcinogenicity tests.
The observations by Harada on the significance of different types of foci obviously have to be extended and confirmed. It should be pointed out that the basophilic foci described in the NCI workshop in 1974 did not distinguish between diffusely basophilic (atypical) and tigroid types.The practice has generally continued among toxicological pathologists not to separate them, although it now appears that they should be subclassified. Eosinophilic foci should probably also be subclassified into those described by Dr. Harada as amphophilic versus the usual ground glass variety. In any event, it is important that investigations into the nature of foci in control animals continue if we are to fully understand the role, if any, of these lesions in the neoplastic process.
SOME FOCI MAY HAVE No RELATIONSHIP
To NEOPLASM As pointed out by Dr. Hirada, the tigroid type of basophilic foci occurred commonly in control Fischer 344 rats and, in his material, were not influenced by hepatacarcinogens. As further evidence that some foci may not be associated with a neoplastic response, there is a recent report that the drug Lovastatin increased the number and size of basophilic and eosinophilic foci in rats, but was not hepatocarcinogenic (4). This is the first reported example known to this author of a substance that induced or enhanced liver foci but was not hepatocarcinogenic in rats, and it suggests that there probably will be other such substances. The effect of Lovastatin on hepatocellular foci was apparent as early as 3 months after beginning administration, but after 2 years oftreatment, the difference between control and treated animals was less apparent. Furthermore, there was no compound-related increase in hepatocellular tumors.
Lovastatin is a cholesterol-lowering agent that acts as a HMG CoA reductase inhibitor. The target enzyme is responsible for a major rate-limiting step in the biosyntheses of cholesterol, i.e., the conversion of HMG CoA to mevalonic acid. MacDonald et a1 also report that simultaneous administration of mevalonic acid and Lovastatin to rats prevented the increase in hepatocellular foci (5). The liver foci increase was, therefore, apparently a compensatory response in the rat livers to the altered cholesterol metabolism.
THE MORPHOUX~ICAL CRITERIA FOR DM~NOSXIW FOCI HAVE CHANGED
As pointed out above, the description of rat liver foci in the 1974 NCI workshop stated that architectural distortion did not occur. There were lesions included in that workshop that slightly compressed surrounding tissue for only a small part of the total circumference and, on this basis, they were classified as neoplastic nodules. In contrast, the rat liver lesion shown on the poster for this meeting (see page 458) clearly compresses the surrounding liver tissue for about one-third of the circumference. Had this poster lesion been considered in the NCI workshop, I
am confident it would have been classified as a neoplastic nodule (or hepatocellular adenoma according to the present terminology).
Experience since 1974 involving many carcinogenicity tests has demonstrated that nodular alteration of the liver architecture and the presence of compression are not sufficient, per se, to classify a lesion as a neoplasm. The lesions occumng in rats with chronic-active liver necrosis or leukemic infiltrates may produce nodular alterations, yet they are not necessarily considered neoplastic (6) . Large hepatocellular foci with hypertrophied cells may also compress surrounding liver and cause distortion of surrounding liver plates, yet they may not exhibit the other histological or cytological features most pathologists require to classify them as neoplasms.
Our morphological criteria have become very broad, allowing many and variable lesions to be lumped under the term altered focus. This is acceptable if there is not sufficient evidence to separate lesions based upon their biological behavior. However, data presented at this meeting suggests there is now evidence to warrant more subclassification of foci than has generally been practiced.
GRADINO OF FOCI OF HEPATOCELLULAR

ALTERATION
Toxicological pathologists often grade non-neoplastic lesions in test animals, particularly those which are prevalent in control animals. In some cases, an adverse effect can be detected only by documenting a dose-related increase in severity of the lesions. Many proliferative lesions, including tumors, are also very prevalent in control animals, and a treatment-related effect involving tumors or other proliferative lesions can be identified with greater confidence and accuracy if the "severity," i.e., the extent of progression, can be assessed (8).
Reliance on lesion incidence alone in marginal or equivocal studies may overlook the most persuasive biological evidence of a positive (or negative) finding, i.e., a dose-related increase in progression. Clearly, in the case of the Fischer 344 rat, in which the incidence of foci is extremely high, a semi-quantitative grading may be necessary to discern a treatment-related increase in the number or size of foci in some studies.
There are many ways that the extent of neoplastic progression can be evaluated but in carcinogenicity tests the methods must be rapid and feasible with H&E-stained sections. A semi-quantitative ranking of proliferative lesions, including tumors, as is done with non-neoplastic lesions can be readily accomplished as part of routine study evaluation. It is generally recognized that the extent of neoplastic progression is reflected by several pathological findings. They are the same findings used to grade (or stage) neoplasms in human oncology, i.e., size, histological and cytological atypia, local invasion, and metastases. Proliferative lesions in test animals may be ranked semi-quantitatively based upon the same findings. Since invasion or metastases are often rare with many of the animal tumors of interest, the grading relies most heavily upon size and histological or cytological atypia. The author generally grades non-neoplastic proliferative lesions and benign tumors as 1-5+, primarily on the basis of size or relative amount of tissue affected. Malignant tumors are graded as 1-5 +, primarily according to size and the extent of atypia. The essential point is that the same pathologist, applying uniform criteria, rank all of the animals in a study. The data generated from such grading may include total lesion incidence, the numbers of animals with each grade, and the mean (average) grade of affected animals. Table I illustrates an example of a marginal carcinogenic finding where the liver tumor rate was significantly increased in high-dose animals (p < 0.05), but in which the grading of foci and tumors does not support a positive finding.
TOXICOLOGIC PATHOLOOY
Without the grading, such data may prompt a conclusion that the test substance is a hepatocarcinogen. However, the complete absence of a dose-related increase in the progression of any proliferative lesion strongly suggests the data are spurious.
SIGNIFICANCE OF FOCI AND THEIR ROLE IN S A F F n h E s s M E N T
This meeting has clearly demonstrated the many uncertainties that remain in attempting to define the significance of rat liver foci. As many have pointed out, at least part of the problem has stemmed from our failure to adhere to a common definition for the lesions studied, such as that based on H&E morphology. Also, until we learn more about the significance of spontaneous foci, it will be difficult to assess the role of these lesions, if any, in carcinogenesis.
Whatever rat liver foci may be, I believe most will agree that, at the least, they represent focal hyperplasia. Epithelial cancer in all tissues begins with hyperplasia, and there are presently no phenotypic features that distinguish physiological from preneoplastic hyperplasia-if, in fact, they differ. Moreover, we cannot identify the point of irreversibility, i.e., the earliest lesions that are committed to progress to neoplasia. Because of these and other uncertainties, we have not generally considered bladder, tracheal, gastric or other hyperplasia in test animals as positive end-points for the determination of'carcinogenicity. Yet, we seem inclined to do just that for rat liver foci, even though there is no more compelling evidence that they are necessarily preneoplastic than that other forms of focal epithelial hyperplasia are necessarily preneoplastic.
Irrespective of the many contributions made by the animal model systems of hepatocarcinogenicity, none have provided the type of evidence necessary to regulate a compound as a carcinogen based solely upon the induction or enhancement of rat liver foci. This conference has, I believe, demonstrated that these lesions have not been adequately defined, nor has their specific relevance to carcinogenesis been established. 345 .
DISCUSSION
Dr. Bunnusch. I agree with most of the statements that you have made. The only exception is your assumption that the tigroid cell population might be irrelevant for the development of hepatic neoplasia. I should like to recall that we induced tigroid cell lesions with aflatoxin, which is certainly a carcinogen.
Dr. Squire. But you said that you could not be certain that the tigroid lesions were the precursors of the tumors and that there were other foci there as well.
Dr. Bunnasch. No, I do not think so. We had only very small numbers of other types of foci and the adenomas which developed usually contained cells that had a tigroid pattern. Therefore, we believe that the tigroid cell population was the precursor of the adenomas. However, I have to admit that we saw the first tigroid cell lesions after 8 weeks in this experiment and only a few nodules after nearly 2 yr. Although the potential of progressing to an adenoma appears to be very low, I am convinced that the tigroid cell lesions are involved in neoplastic development. They should be separated from the other types of lesions; however, the conception that all types of foci are involved in neoplastic development still appears to be true. Dr. Vesselinovitch. But in one serial section you may find only 20% compression while in the next section you find 80%. That is quite a pitfall.
Dr. Squire. That is correct. That is true of pathology which is based on samples. The only way to make sure that you do not miss anything is to serial section an organ. We can say that with respect to invasion, atypia, with any parameter.
Dr. Vesselinovitch. What made you change your mind with respect to supporting the view that compression was the hallmark of neoplasia?
Dr. Squire. The world is changing its mind. I think all of us have seen more nodular lesions in the past several years, including those in Fischer rat leukemia. I think those lesions were part of the stimulus that convinced us that compression, perse, does not reflect autonomy. We always thought compression reflected autonomy and that was what really told us a proliferative lesion was a neoplasm since it was growing at the expense of surrounding tissue. However, I think compression in itself is not the ultimate criterion. Henry, do you have any comment on the Lovastatin lesions?
Dr. Pitot. I agree with you that when we first observed these lesions, we thought that these animals would blossom out with carcinomas but they never did. I do think, however, that the data argues that Lovastatin, if anything, has a slight promoting action because of the fact that Lovastatin induced a certain number of foci but after a time, the number in the control caught up with the experimental. That is basically what happens when you look at b a dground foci with a promoting agent, namely the number in your controls are eventually going to catch up with that in the treated. The fact that they did not disappear when the drug was removed merely indicated that there was sufficient endogenous promoting factors to maintain the number.
Unidentikd. Bob, would you object to a classification system that just went carcinoma and foci and then grade the foci since we do not seem to be sure what an adenoma is?
Dr. Squire. The problem is that could logically lead to classifying everything as simply a hepatoproliferative lesion and grading them as 1 + through 5 +, which would not be adequate for safety assessment.
